News >

Radiation Avoidable in Some Wilms Tumor Patients With Lung Metastases

Jason Harris
Published: Monday, Apr 23, 2018

Jeffrey S. Dome, MD, PhD

Jeffrey S. Dome, MD, PhD
A novel risk stratification and treatment approach led to enhanced clinical outcomes overall, as well as the successful omission of radiotherapy (RT) for some patients with stage IV favorable histology Wilms tumor and pulmonary metastases, according to findings from the COG AREN0533 published in the Journal of Clinical Oncology. 

Twelve patients reported 22 adverse events (AEs)—8 in the DD4A group and 14 in the Regimen M group. One patient in the DD4A group died due to surgical complications within the first 6 weeks, and 1 patient receiving Regimen M died of undetermined cause. Investigators found that the rate of grade ≥3 nonhematologic AEs was low in the Regimen M group, the most common being infections and infestations (14.1%) and hypokalemia (5.4%).
Dix DB, Seibel NL, Chi YY, et al. Treatment of stage IV favorable histology Wilms tumor with lung metastases: a report from the Children’s Oncology Group AREN0533 study [published online April 16, 2018]. J Clin Oncol. doi: 10.1200/JCO.2017.77.1931.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Individualizing Treatment After Second-Line Therapy for Patients With mCRCAug 29, 20191.0
Community Practice Connections™: Immunotherapeutic Strategies with the Potential to Transform Treatment for Genitourinary CancersAug 29, 20191.0
Publication Bottom Border
Border Publication